Polpharma Biologics and Fresenius Kabi Sign Licensing Agreement for Proposed Vedolizumab Biosimilar PB016

Contributed by: Business Wire

Logo

Tags

Biotechnology

General Health

Other Health

Health

Pharmaceutical

Fresenius Kabi

More Like This

PR Newswire associated0

Zentiva and Lupin Sign License and Supply Agreement for TNF alpha inhibitor biosimilar medicine

Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars

PR Newswire associated0

Bone Health: Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

PR Newswire associated0

Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

PR Newswire associated0

mAbxience Announces European Commission Approval of Denosumab Biosimilars

Celltrion Receives Positive CHMP Opinion for Three Biosimilars in the European Union

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC